Dr. Guru Sonpavde outlines how EV pembrolizumab and GEMCIS-durvalumab are reshaping neoadjuvant therapy for MIBC, while cystectomy remains the standard of care. He explains that bladder preservation with chemoradiation may be considered in carefully selected patients, though it remains investigational without phase III data. Emerging tools like ctDNA, cystoscopy, and urine tumor DNA may improve patient selection, but for now, treatment decisions rely on shared decision-making and careful risk assessment.
ZUSDURI (Mitomycin) Demonstrates Sustained Efficacy Across EORTC Risk Groups in Recurrent NMIBC
ZUSDURI (mitomycin) delivers durable tumor control in recurrent low‑grade, intermediate‑risk NMIBC, with 79.6% complete responses at three months and 72.2% event-free survival at 24 months. Effective across all EORTC risk groups, it offers a promising option for bladder preservation and long-term disease management.
